[A23-35] Lasmiditan (migraine) – Benefit assessment according to §35a Social Code Book V
Last updated 17.07.2023
Project no.:
A23-35
Commission:
Commission awarded on 17.04.2023 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Head and nerves
Indication:
Adults who need acute treatment in the headache phase of migraine attacks, with or without aura
Result of dossier assessment:
Added benefit not proven
Note:
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.